Yazar "Sen, F." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Extraction of Cu2+ and Co2+ by using Tricholoma populinum loaded onto Amberlite XAD-4
    (Springer, 2021) Ozdemir, S.; Kilinc, E.; Poli, A.; Romano, I; Nicolaus, B.; Mustafov, S. D.; Sen, F.
    In this work, an alternative preconcentration process suggested based on usingTricholoma populinumas a fungal biosorbent for the sensitive preconcentration of Cu(2+)and Co2+. Amberlite XAD-4 was utilized for the loading of the biomass in solid-phase extraction (SPE) procedure. It was found thatT.populinumloaded with XAD-4 resin was a selective biosorbent for the preconcentration of Cu(2+)and Co2+. Experimental variables in SPE procedure such as pH, the flow rate of the sample, type and concentration of eluent, amount ofT.populinumand of XAD-4 resin, sample volume, and potential interfering ion effect were studied. Surface functionalities of the metal-loaded and metal-unloaded biosorbent were determined by comparing Fourier transform infrared spectroscopy spectra and scanning electron microscopy images. Limit of detection values for Cu(2+)and Co(2+)were found as 0.034 and 0.019 ng mL(-1), respectively. The linear range was found as 0.2-15 ng mL(-1)for both analytes. Relative standard deviation values were found as lower than 3.0%. Certified reference materials were applied for process validation, and also, the concentrations of Co(2+)and Cu(2+)were investigated in real water, vegetable, and soil samples. So, the method developed could be utilized for the preconcentrations of Cu(2+)and Co(2+)for routine analysis. This method can be used as an inexpensive and accessible alternative to GF-AAS or ICP-MS methods.
  • [ X ]
    Öğe
    Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial
    (Churchill Livingstone, 2013) Saip, P.; Eralp, Y.; Sen, F.; Karaca, H.; Ozkan, M.; Cetin, B.; Benekli, M.
    Background: The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine in women with HER2 positive metastatic or recurrent breast cancer. Methods: Twenty-nine patients were enrolled. The primary objectives were response and clinical benefit (CB) rates, secondary objectives were toxicity, response duration and progression free survival. Patients received 1250 mg oral lapatinib continuously once daily and intravenous vinorelbine 20-25 mg/m(2) on days 1 and 8, every 3 weeks. Results: Although 25 patients were evaluable for response, according to intend to treat analysis of 28 patients; 14% had confirmed partial response (PR) and 36% had stable disease more than 24 weeks with a CB rate of 50%. Sixty four percent of the patients suffered from grade 3-4 hematologic and 18% from grade 3 extra-hematologic toxicities. Conclusion: The results of this trial provide evidence to further investigate the potential of this combination for patients unsuitable for trastuzumab or who become refractory to trastuzumab. (C) 2013 Elsevier Ltd. All rights reserved.